Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1985-1989  (1)
  • Prospective randomized trial  (1)
  • Oxyfedrin
  • 1
    ISSN: 1435-2451
    Keywords: Breast cancer ; Prospective randomized trial ; Mammacarcinom ; Randomisierte Studie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Operatives Vorgehen, Resektion (R) versus modifiziert radikale Mastektomie (M) und M versus klassisch radikaler Mastektomie (RM) und Fragen der adjuvanten Therapie, Chemound Chemoimmunotherape gegenüber einer Kontrollgruppe wurden 241 Patientinnen nach rezidivfreiem und absolutem Überleben beurteilt. Die mediane Beobachtungszeit beträgt 48 Monate. R schnitt gegenuber M in beiden Parametern signifikant schlechter ab. Dagegen fand sich kein Unterschied zwischen M and RM. Im Gegensatz zur Auswertung nach 30 min konnte kein signifikanter Unterschied bei den adjuvant behandelten Patientinnen nach 48 Monaten gefunden werden. Patientinnen mit receptor-negativen, Grad III Tumoren überlebten mit Chemotherapie signifikant besser.
    Notes: Summary In 241 patients, with a median observation time of 48 months, surgical treatment, partial resection (R) versus modified radical mastectomy (M) and M versus Halsted's procedure (RM), as well as adjuvant treatment forms, chemotherapy and chemoimmunotherapy versus an untreated control group were all evaluated. Whereas M showed significantly better results (RFS, absolute survival) than R, no difference could be observed when comparing M and RM. At 48 months no significant differences could be detected for patients with adjuvant chemotherapy, but patients bearing receptornegative, grade III tumors did significantly better when receiving chemotherapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...